Table 3.
The cut-off values of p2PSA derivatives and the PHI in predicting ≥pT3 cancer, high-risk disease, a positive surgical margin, and seminal vesical invasion at a sensitivity of 90%.
| Outcome | PSA derivatives | Cut-off | Specificity |
|---|---|---|---|
| Cancer stage ≥pT3 | tPSA | ≥5.95 | 16.7% |
| p2PSA | ≥10.51 | 15.0% | |
| %p2PSA | ≥1.21 | 30.0% | |
| PHI | ≥33.92 | 26.7% | |
| High-risk disease | tPSA | ≥5.95 | 18.2% |
| p2PSA | ≥10.51 | 16.4% | |
| %p2PSA | ≥1.12 | 29.1% | |
| PHI | ≥33.92 | 29.1% | |
| Positive surgical margin | tPSA | ≥5.34 | 16.7% |
| p2PSA | ≥10.46 | 14.6% | |
| %p2PSA | ≥1.17 | 33.3% | |
| PHI | ≥33.92 | 31.3% | |
| Seminal vesical invasion | tPSA | ≥7.22 | 25.0% |
| PHI | ≥61.26 | 66.3% |
PSA: prostate specific antigen; tPSA: total PSA; p2PSA: [−2]pro PSA; %p2PSA = (p2PSA/fPSA × 1000) × 100; PHI: Prostate Health Index.